Abstract

Abstract Background: This study was conducted to identify genetic polymorphisms associated with the prognosis of patients with early stage non-small cell lung cancer (NSCLC). Materials and Methods: We genotyped 1,969 potentially functional single nucleotide polymorphisms (SNPs) of 1,151 genes using the Affymetrix custom-made GeneChip, which were related to the development and progression of cancer, in 166 NSCLC patients who underwent curative surgical resection. A replication study was performed on an independent cohort of 626 patients. Results: Fifty six SNPs which were associated with both overall survival (OS) and disease-free survival (DFS) with log-rank P values lower than 0.05 in a discovery set were selected for validation. Among the 56 SNPs, five SNPs (guanine nucleotide binding protein, beta polypeptide 2-like 1 [GNB2L1] rs1279736C>A and rs3756585T>G, complement component 3 [C3] rs2287845T>C, p300/CBP-associated factor [PCAF] rs17006625A>G, and pericentriolar material 1 [PCM1] rs17691523C>G) were found to be significantly associated with survival outcomes in the same direction as the discovery set. In combined analysis, the rs1279736C>A and s3756585T>G were most significantly associated with OS and DFS in multivariate analysis (P for OS = 4x10-5 and 7x10-5, respectively; and P for DFS = 0.003, both; under a codominant model). Conclusions: We identified five SNPs as markers for prognosis of patients with surgically resected NSCLC. Citation Format: Shin Yup Lee, Yi Young Choi, Hyo-Sung Jeon, Jin Eun Choi, Hyo-Gyoung Kang, Seung Soo Yoo, Eung Bae Lee, Won Kee Lee, Jaehee Lee, Seung Ick Cha, Chang Ho Kim, Ji Woong Son, Jae Yong Park. Polymorphisms in cancer-related genes and survival in early stage non-small cell lung cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4721. doi:10.1158/1538-7445.AM2014-4721

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call